Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Elmed Eisai to Be Renamed “Elmed”, Move Headquarters to Toyama
December 5, 2018
- Takeda Family Member Comes Forward for Final Appeal to Veto Shire Deal, but Admits Uphill Battle
December 4, 2018
- Takeda Inks US$3.7 Billion Loan Accord with JBIC
December 4, 2018
- Ninlaro Shows 39% Improvement in PFS in Post-Transplant Multiple Myeloma Patients: Takeda
December 4, 2018
- Astellas Launches Sakigake-Designated AML Drug Xospata
December 4, 2018
- Fujifilm Toyama Chemical Licenses Cancer “Theragnostic” Agent to Novartis Subsidiary
December 4, 2018
- MSD Japan Chief Voices High Hopes for Keytruda Label Expansions
December 3, 2018
- With Current R&D Model Reaching Its Limit, Industry Going Digital to Boost Efficiency: Astellas Chairman
December 3, 2018
- Lilly Launches Breast Cancer Drug Verzenio
December 3, 2018
- AbbVie Files Maviret for Pediatric Use for Age 12 and Older
December 3, 2018
- Olympus to Launch Japan Clinical Study of Regenerative Medicine Product for Traumatic Cartilage Defects
December 3, 2018
- ADHD Treatments to Reap 50% Growth in 2026, Despite Shrinking CNS Market: Fuji Keizai
December 3, 2018
- US FDA Approves Astellas’ AML Treatment Xospata
November 30, 2018
- Celgene Files Otezla for Additional Indication of Oral Ulcers due to Behcet’s Disease
November 30, 2018
- JT to Return Rights to Gilead’s 6 HIV Agents in 2019, Get 63.1 Billion Yen
November 30, 2018
- Kowa Reps Continue Heavy GP Detailing for Parmodia in August: Anterio
November 30, 2018
- Fycompa Hits Primary Endpoint in Monotherapy PIII, Eisai Eyes Filing by March-End
November 29, 2018
- Daiichi Sankyo, Roche to Collaborate on CDx Development for DS-8201
November 29, 2018
- JCR Launches Japan’s 1st Fabrazyme Biosimilar
November 29, 2018
- Daiichi Sankyo’s Herceptin Biosimilar Hits Shelves, Nippon Kayaku/Celltrion Earn Breast Cancer Nod
November 29, 2018
ページ
International regulators are increasingly moving away from comparative efficacy studies (CES) in biosimilar development — long considered a default requirement…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…